DIVISLAB

Data path: financials for DIVISLAB are currently sourced via the US ADR cross-listing (NYSE/NASDAQ). The fair value and score on this page reflect the latest cached compute against that data path. A direct NSE data path is in active development; values will refresh once it lands. How our data sourcing works →

Divi's Laboratories Limited

DIVISLAB · Pharma · NSE

₹6,753

Current Market Price

Above Fair Value

Fair Value (DCF)

₹2,481

Discount to FV

-63.3%

Valuation engine: DCF

Updated 4m ago

DCF Sensitivity →

YieldIQ Score

40/100

Piotroski F-Score

5/9

Economic Moat

None

Confidence

51%

ROE

15.3%

Debt/Equity

0.00

WACC

9.5%

Market Cap

₹1.79 Lakh Cr

Quality & Valuation

Neutral model outputs — no recommendations.

ROCE

23.1%

Return on capital employed

EV / EBITDA

46.1×

Enterprise multiple

Debt / EBITDA

0.0×

Leverage vs earnings

Interest Coverage

148.3×

EBIT covers interest

Current Ratio

5.43×

Short-term liquidity

Asset Turnover

0.50×

Revenue per ₹ of assets

Revenue CAGR (3Y)

-74.8%

3-year revenue growth

Revenue CAGR (5Y)

-57.3%

5-year revenue growth

DCF Scenario Analysis

vs CMP ₹6,753

Bear case

Discount -352.2%

Base case

Discount -172.1%

Bull case

Discount -102.9%

Ratio Trends

DIVISLAB · last 9 annual periods

ROE

15.3%

min 11.8%max 25.2%

ROCE

23.1%

min 16.0%max 31.4%

Operating Margin

—

min —max —

Debt / Equity

0.00×

min 0.00×max 0.00×

PE

0.7×

min 0.5×max 0.8×

EV / EBITDA

—

min —max —

Historical Financials

DIVISLAB · Annual, last 5 years· amounts in ₹Cr unless noted

Metric
2022
NSE_XBRL
2023
NSE_XBRL
2024
NSE_XBRL
2025
yfinance
2026
yfinance
CAGR
Revenue₹8799 Cr₹7665 Cr₹7796 Cr₹9360 Cr₹10.6K Cr+4.7%
EBITDA₹3995 Cr₹2712 Cr₹2544 Cr₹3320 Cr₹3874 Cr-0.8%
EBIT₹3684 Cr₹2369 Cr₹2166 Cr——-12.4%
PAT₹2960 Cr₹1824 Cr₹1600 Cr₹2191 Cr₹2568 Cr-3.5%
EPS (diluted)₹111.52₹68.69₹60.27——-14.3%
CFO₹1912 Cr₹2459 Cr₹1261 Cr₹1653 Cr₹2738 Cr+9.4%
CapEx₹-713 Cr₹-473 Cr₹-1003 Cr₹-1438 Cr₹-2520 Cr—
FCF₹1199 Cr₹1986 Cr₹258 Cr₹215 Cr₹218 Cr-34.7%
Total Assets₹13.4K Cr₹14.4K Cr₹15.5K Cr₹16.9K Cr₹20.0K Cr+10.6%
Total Debt₹3.7 Cr₹4.0 Cr₹3.0 Cr₹4.0 Cr₹7.0 Cr+17.4%
Shareholders' Equity₹11.7K Cr₹12.8K Cr₹13.6K Cr₹15.0K Cr₹16.8K Cr+9.3%

CAGR computed across the visible window. Signs reverse if start value is zero or negative.

Peer Comparison

DIVISLAB vs 5 closest peers by market-cap band

PeerMoSScoreVerdictROEPE
TORNTPHARM

Torrent Pharmaceuticals Limited

-64.1%40Above Fair Value25.8%—
CIPLA

Cipla Limited

-11.5%45Near Fair Value11.3%25.5×
DRREDDY

Dr. Reddy's Laboratories Limited

+19.7%55Near Fair Value11.4%24.4×
ZYDUSLIFE

Zydus Lifesciences Limited

+28.9%63Near Fair Value18.6%—
LUPIN

Lupin Limited

+35.6%50Near Fair Value23.8%19.8×

Click a ticker to view its fair-value analysis.

Dividend History

9 ex-dividend events on file. Source: NSE corporate-actions feed.

Total paid (5Y)

₹140.00/sh

Last payout

2025-07-25

₹30.00

Peak payout

₹30.00

Trailing yield

0.44%

Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).

AI Analysis Summary

Model-generated description of metrics. Not investment advice. Divi's Laboratories Limited (DIVISLAB.NS) trades at 6753.00 vs a model fair value of 2481.45, a gap of -63.3%. Piotroski F-score: 5/9. Mo...

Read full AI analysis →

Reverse DCF

Market-implied growth

What FCF growth is priced in →

Risk Analysis

Volatility & drawdown

Risk profile of DIVISLAB →

DuPont

ROE decomposition

Why ROE is what it is →

Technicals

RSI, MACD, MAs

Reference indicators →

News & Filings

Recent activity

BSE filings + news for DIVISLAB →

Compare

Head-to-head with peers

Compare DIVISLAB side by side →

Run Full Interactive Analysis

Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.

Analyse DIVISLABNow →

Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.